Н.Ю. Григорьева, М.В. Майорова, М.О. Самолюк, Т.П. Илюшина
Федеральное государственное бюджетное образовательное учреждение высшего образования «Приволжский исследовательский медицинский университет», Министерства здравоохранения Российской Федерации, ГБУЗ НО «Городская клиническая больница №5» г. Нижний Новгород
Целью настоящего исследования явилась оценка окислительного стресса и эндотелиальной дисфункции у больных хронической обструктивной болезнью легких (ХОБЛ), имеющих сопутствующую сердечно-сосудистую патологию.
ключевые слова: коморбидность, ишемическая болезнь сердца, артериальная гипертензия, хроническая обструктивная болезнь легких, дисфункция эндотелия, окислительный стресс

для цитирования: Н.Ю. Григорьева, М.В. Майорова, М.О. Самолюк, Т.П. Илюшина. Роль эндотелиальной дисфункции и окислительного стресса в формировании сердечно-сосудистой коморбидности у больных хронической бронхолегочной патологией. Неотложная кардиология и кардиооваскулярные риски, 2019, Т. 3, № 2, С. 683–688

The role of endothelial dysfunction and oxidative stress in the formation of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease
N.Yu. Grigoryeva, M.V. Mayorova, M.O. Samoluk, T.P. Ilyushina
The purpose of this study was to evaluate oxidative stress and endothelial dysfunction in patients with chronic obstructive pulmonary disease (COPD) who had concomitant cardiovascular pathology.
keywords: сomorbidity, coronary heart disease, arterial hypertension, chronic obstructive pulmonary disease, endothelial dysfunction oxidative stress

for references: N.Yu. Grigoryeva, M.V. Mayorova, M.O. Samoluk, T.P. Ilyushina. The role of endothelial dysfunction and oxidative stress in the formation of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease. Neotlozhnaya kardiologiya i kardioovaskulyarnye riski [Emergency cardiology and cardiovascular risks], 2019, vol. 3, no. 2, pp. 683–688

1. Capone C., Faraco G., Coleman C., Young C.N., Pickel V.M., Anrather J., Davisson R.L., Iadecola C. Endothelin-1-dependent neurovascular dysfunction in chronic intermittent hypoxia. Hypertension, 2012, vol. 60, no. 1, рр. 106-13. DOI: 10.1161/HYPERTENSIONAHA.112.193672.
2. Cavaillès A., Brinchault-Rabin G., Dixmier A., Goupil F., Gut-Gobert C., Marchand-Adam S., Meurice J.-C. Morel H., Person-Tacnet C., Leroyer C., Diot P. Comorbidities of COPD. European Respiratory Review, 2013, vol. 22, pp. 454 –475. DOI: 10.1183/09059180.000086.
3. Smetneva N.S., Vikent’ev V.V., Zav’yalova S.A., Popkova A.M., Maly’shev I.Y. Rol’ vospalitel’nykh faktorov v razvitii serdechno-sosudistoj patologii pri khronicheskoj obstruktivnoj bolezni legkikh [ The role of inflammatory factors in the development of cardiovascular disease in chronic obstructive pulmonary disease]. Fundamental’nye issledovaniya, 2013, vol. 3, no. 1, рр. 162–165. (In Russian)
4. Ives S.J, Harris R.A, Witman M.A. Fjeldstad A.S., Garten R.S., McDaniel J., Wray D.W., Richardson R.S. Vascular dysfunction and chronic obstructive pulmonary disease: the role of redox balance. Hypertension, 2014, vol. 63, no. 3, pp. 459–467. DOI: 10.1161/HYPERTENSIONAHA.113.02255.
5. Rahman T., Hosen I., Towhidul Islam M.M., Shekhar H. U. Oxidative stress and human health, Advances in Bioscience and Biotechnology. Hossain Uddin Shekhar, 2012, vol. 3, no. 7, pp. 997-1019. DOI: 10.4236/ abb. 2012. 327123.
6. Park K.H., Park W.J. Endothelial dysfunction: clinical implications in cardiovascular disease and therapeutic approaches. J Korean Med Sci, 2015, vol. 30, no. 9, pp. 1213–1225. DOI: 10.3346/jkms.2015.30.9.1213.
7. Mordi I., Mordi N., Delles C., Tzemos N. Endothelial dysfunction in human essential hypertension. J Hypertension, 2016, vol. 34, no. 8, pp. 1464–1472. DOI:10.1097/HJH.0000000000000965.
8. Atsou K., Chouaid C., Hejblum G. Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review. BMC Med, 2011, vol. 9, pp. 7. DOI: 10.1186/1741-7015-9-7.
9. Singh D., Agusti A., Anzueto A., Barnes P.J., Bourbeau J., Celli B.R., Criner G.J., Frith P., Halpin D.M.G., Han M., López Varela M.V., Martinez F., Montes de Oca M., Papi A., Pavord I.D., Roche N., Sin D.D., Stockley R., Vestbo J., Wedzicha J.A., Vogelmeier C. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J, 2019, vol. 53, no. 5, pii: 1900164. DOI: 10.1183/13993003.00164-2019.
10. Zykov K.А., Sokolov E.I. Novaya klassifikatsiya khronicheskoj obstruktiv-noj bolezni legkikh: novye vozmozhnosti ili novye problemy? [New classification of chronic obstructive pulmonary disease: new opportunities or new challenges] Consilium Medicum, 2013, vol. 15, no. 5, pp. 42–47. (In Russian).
11. Starodubov V.I., Leonov S.А., Vajsman D.SH. Аnaliz osnovnykh tendentsij izmeneniya zabolevaemosti naseleniya khronicheskimi obstruktivnymi boleznyami legkikh i bronkhoehktaticheskoj bolezn’yu v Rossijskoj Federatsii v 2005-2012 godakh. [Analysis of the main trends in the incidence of chronic obstructive pulmonary disease and bronchiectatic disease in the Russian Federation in 2005-2012]. Meditsina, 2013, vol. 1, no. 4, pp. 1–31. (In Russian).
12. Leshhenko I.V., Baranova I.I. Biomarkery vospaleniya pri khronicheskoj obstruktivnoj bolezni legkikh [Biomarkers of inflammation of chronic obstructive pulmonary disease]. Pul’monologiya, 2012, no. 2, рр. 108–117. (In Russian)
13. Almagro P., Cabrera F.J., Diez J., Boixeda R., Recio J., Mercade J., Yun S., Soriano J.B. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the ESMI study. Eur Res J, 2015, vol. 46, no. 5, pp. 850–853.
14. Anderson W., Lipworth B., Rekhraj S., Struthers A.D., George J. Left Ventricular Hypertrophy in Chronic Obstructive Pulmonary Disease without Hypoxaemia: The Elephant in the Room? Chest, 2013, vol. 143, no. 1, pp. 91–97. DOI: 10.1378/ chest.12-0775.
15. Gkaliagkousi E., Gavriilaki E., Triantafyllou A., Douma S. Clinical Significance of Endothelial Dysfunction in Essential Hypertension. Curr Hypertens Rep, 2015, vol. 17, no. 11, pp. 85. DOI: 10.1007/s11906-015-0596-3.
16. Vertkin А.L., Skotnikov А.S., Gubzhokova O.M. Komorbidnost’ pri khronicheskoj obstruktivnoj bolezni legkikh: rol’ khronicheskogo sistemnogo vospaleniya i kliniko-farmakologicheskie nishi roflumilasta [Comorbidity in chronic obstructive pulmonary disease: the role of chronic systemic inflammation and clinical and pharmacological niches of roflumilast]. Lechashhij vrach, 2013, no. 11, pp. 85–88. (In Russian).
17. Li V.V., Zadionchenko V.S., Adasheva T.V., Pavlov S.V., Malinicheva Yu.V., Samorukova E.I., Salmanova E.A., Lugovcova J.V. Аrterial’naya gipertoniya u bol’nykh khronicheskoj obstruktivnoj bolezn’yu legkikh – v poiskakh fenotipov. CHast’ 1 [Arterial hypertension and patients with chronic obstructive pulmonary disease-in search of phenotypes. Part 1]. Аrkhiv vnutrennij meditsiny, 2013, no. 1, no. 9, pp. 19–24. (In Russian).
18. Münzel T., Camici G.G., Maack C., Bonetti N.R., Fuster V., Kovacic J.C. Impact of oxidative stress on the heart and vasculature: Part 2 of a 3-Part series. J Am Cardiol, 2017, vol. 70, no. 2, pp. 212–229. DOI: 10.1016/j.jacc.2017.05.035.
19. Leurgans T.M., Bloksgaard M., Irmukhamedov A., Riber L.P., De Mey J.G.R. Relaxing responses to hydrogen peroxide and nitric oxide in human pericardial resistance arteries stimulated with endothelin-1. Basic & clinical pharmacology & toxicology, 2018, vol. 122, no. 1, рр. 74–81. DOI: 10.1111/bcpt.12843.
Формат файла: pdf (463.82 Кб)